This company listing is no longer active
4541 Stock Overview
Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, and distributes various pharmaceutical products. More details
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Nichi-Iko Pharmaceutical Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | JP¥35.00 |
52 Week High | JP¥804.00 |
52 Week Low | JP¥35.00 |
Beta | -0.66 |
11 Month Change | -20.45% |
3 Month Change | -57.83% |
1 Year Change | -95.49% |
33 Year Change | -97.27% |
5 Year Change | -97.95% |
Change since IPO | -98.27% |
Recent News & Updates
Recent updates
Shareholder Returns
4541 | JP Pharmaceuticals | JP Market | |
---|---|---|---|
7D | -2.8% | -5.6% | -0.5% |
1Y | -95.5% | 6.4% | 10.8% |
Return vs Industry: 4541 underperformed the JP Pharmaceuticals industry which returned 9% over the past year.
Return vs Market: 4541 underperformed the JP Market which returned 1.6% over the past year.
Price Volatility
4541 volatility | |
---|---|
4541 Average Weekly Movement | 17.0% |
Pharmaceuticals Industry Average Movement | 3.6% |
Market Average Movement | 3.8% |
10% most volatile stocks in JP Market | 7.6% |
10% least volatile stocks in JP Market | 2.1% |
Stable Share Price: 4541's share price has been volatile over the past 3 months.
Volatility Over Time: 4541's weekly volatility has decreased from 25% to 17% over the past year, but is still higher than 75% of JP stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1947 | 2,656 | Shingo Iwamoto | www.nichiiko.co.jp |
Nichi-Iko Pharmaceutical Co., Ltd. manufactures, sells, and distributes various pharmaceutical products. It operates through two segments, Nichi-Iko Group and Sagent Group. The company primarily focuses on the production of generic drugs.
Nichi-Iko Pharmaceutical Co., Ltd. Fundamentals Summary
4541 fundamental statistics | |
---|---|
Market cap | JP¥24.64b |
Earnings (TTM) | -JP¥160.44b |
Revenue (TTM) | JP¥182.88b |
0.1x
P/S Ratio-0.2x
P/E RatioIs 4541 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4541 income statement (TTM) | |
---|---|
Revenue | JP¥182.88b |
Cost of Revenue | JP¥195.69b |
Gross Profit | -JP¥12.81b |
Other Expenses | JP¥147.63b |
Earnings | -JP¥160.44b |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -227.92 |
Gross Margin | -7.01% |
Net Profit Margin | -87.73% |
Debt/Equity Ratio | -389.9% |
How did 4541 perform over the long term?
See historical performance and comparison